ClinicalTrials.gg

Leiomyosarcoma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 177 studies for Leiomyosarcoma across more than 10 countries. 35 are recruiting or about to start. 73 of them are mainly about Leiomyosarcoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
87
Recruiting
31
Terminated
21
Active, not recruiting
14
Status unknown
13
Withdrawn
6

Phase

Phase 2
107
Phase 1
40
Phase 3
23
Early Phase 1
1

Where

United States
108
France
27
United Kingdom
22
Spain
19
Germany
19
Canada
16

Who develops what

Add Leiomyosarcoma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 0 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DoxorubicinRecent, repeated
Evidence
  • NCT06277154 · HRYZ Biotech Co. · Phase 2 · live · background · “Doxorubicin” · registered Feb 2024
  • NCT06088290 · PharmaMar · Phase 3 · live · background · “Doxorubicin” · registered Sep 2023
  • NCT04996004 · Pfizer · Phase 2 · background · “Doxorubicin” · registered Aug 2021
  • NCT03420014 · Philogen S.p.A. · Phase 2 · live · comparator · “Doxorubicin” · registered Jan 2018
  • NCT02451943 · Eli Lilly and Company · Phase 3 · background · “Doxorubicin” · registered May 2015
Hoffmann-La Roche10% of its industry studiesUS: off-patent, 14 generics marketed22 studies

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Leiomyosarcoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 4 open · Immune checkpoint inhibitors 3 open · Alkylating agents 2 open · Antimitotic agents 7 · HDAC inhibitors 5

Coming up

15studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 31 Leiomyosarcoma studies recruiting now, 25 (81%) set no upper age limit and 4 (13%) stop at 75 or younger. 6 (19%) take children under 18. 3 (10%) are for women only and 0 (0%) for men only; 1 (3%) take healthy volunteers.

Recruiting studies that take each age, of 31
AgeWomenMen
104 (13%)4 (13%)
1830 (97%)27 (87%)
3030 (97%)27 (87%)
4029 (94%)26 (84%)
5029 (94%)26 (84%)
6530 (97%)27 (87%)
7529 (94%)26 (84%)
8527 (87%)25 (81%)

Across all 177 studies, recruiting or not: 11% stop at 75 or younger and 2% at 65; 23% take children; 16% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leiomyosarcoma studies take

Of 41 phase 2 interventional studies under Leiomyosarcoma, half reached primary completion within 62 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 262 mo35–80 · 41 studies—61 mo35–80 · 38 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 177. Browse all 177 → or search them.